Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (14,102,000)	$ (1,635,000)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(622,000)	(1,313,000)
Loss from continuing operations, net of taxes	(13,480,000)	(322,000)
Depreciation and amortization	2,986,000	2,821,000
Amortization of debt issuance costs	164,000	166,000
Deferred tax (benefit) expense	(3,095,000)	107,000
Recovery of bad debt reserves	(336,000)	(27,000)
Loss (gain) on disposal of property and equipment	16,000	(23,000)
Impairment loss on tangible assets	1,816,000
Impairment loss on intangible assets	8,288,000
Issuance of common stock for services	178,000	220,000
Stock-based compensation	69,000	62,000
Changes in operating assets and liabilities of continuing operations
Restricted cash	35,000
Accounts receivable	(140,000)	(164,000)
Unbilled receivables	1,808,000	1,354,000
Prepaid expenses, inventories and other assets	2,247,000	707,000
Accounts payable, accrued expenses and unearned revenue	(1,869,000)	(3,404,000)
Cash (used in) provided by continuing operations	(1,313,000)	1,497,000
Cash used in discontinued operations	(710,000)	(1,233,000)
Cash (used in) provided by operating activities	(2,023,000)	264,000
Cash flows from investing activities:
Purchases of property and equipment	(104,000)	(338,000)
Proceeds from sale of property and equipment	30,000	27,000
Proceeds from sale of SYA subsidiary		50,000
Payment to finite risk sinking fund	(76,000)	(30,000)
Cash used in investing activities of continuing operations	(150,000)	(291,000)
Proceeds from sale of property of discontinued operations	46,000
Cash used in investing activities	(104,000)	(291,000)
Cash flows from financing activities:
Repayments of revolving credit facility borrowings	(41,223,000)	(49,476,000)
Borrowing on revolving credit facility	44,137,000	49,783,000
Proceeds from issuance of common stock upon exercise of warrants/options	156,000	10,000
Proceeds from stock subscription - Perma-Fix Medical S.A.	64,000	971,000
Payment of debt issuance costs	(97,000)	(13,000)
Principal repayments of long term debt	(1,199,000)	(1,742,000)
Principal repayments of long term debt-related party	(1,000,000)	(1,125,000)
Cash provided by (used in) financing activities of continuing operations	838,000	(1,592,000)
Effect of exchange rate changes on cash	(1,000)	(63,000)
Decrease in cash	(1,290,000)	(1,682,000)
Cash at beginning of period	1,435,000	3,680,000
Cash at end of period	145,000	1,998,000
Supplemental disclosure:
Interest paid	309,000	404,000
Income taxes paid	41,000	116,000
Proceeds from stock subscription for Perma-Fix Medical S.A. held in escrow		$ 67,000